Rifabutin prophylaxis against Mycobacterium avium complex infections in HIV-infected patients: impact on the incidence of campylobacteriosis.
Following the observation of the decreasing occurrence of campylobacteriosis in HIV-infected patients. This study examines the incidence of campylobacteriosis in patients who had received rifabutin prophylaxis against Mycobacterium avium complex (MAC) infection compared with the incidence observed among patients treated before the advent of rifabutin. A retrospective analysis (February 1992 to November 1995) was conducted in a hospital HIV inpatient unit. The study included two patient groups: 73 HIV-infected patients with CD4 counts of < 100 cells/microL (mean 30 cells/microL) who were treated between February 1992 and July 1993 and who had not received rifabutin prophylaxis (Group R-), as well as 90 HIV-infected patients with CD4 counts of < 100 cells/microL (mean 22 cells/microL) who had received rifabutin 300 mg/day as primary prophylaxis against MAC bacteremia between July 1993 and November 1995 (Group R+). For the patient population as a whole, 20 episodes of campylobacter infection were observed in 13 patients. Causative pathogens were Campylobacter jejuni (n = 10), C. coli (8), and unidentifiable (2). Seventeen episodes (in 12 patients) of campylobacter infection occurred in Group R- versus 3 episodes (in 2 patients) in Group R+ (p < 0.0005). The rate of symptomatic infection per 100 patient-months was 0.251 in Group R+ versus 2.02 in Group R-. The results of this study indicate that rifabutin prophylaxis was associated with a decrease in the rate of campylobacter infection in HIV-infected patients. These findings are supported by evidence that rifabutin is active against C. jejuni in vitro.
Pulik
M
M
Department of Hematology, Victor Dupouy Hospital, Argenteuil, France.
Genet
P
P
Leturdu
F
F
Lionnet
F
F
Louvel
D
D
Touahri
T
T
D017088:AIDS-Related Opportunistic Infections / Q000517:prevention & control*; D000328:Adult; D000904:Antibiotics, Antitubercular / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count / Q000187:drug effects; D002169:Campylobacter Infections / Q000453:epidemiology / Q000401:mortality / Q000517:prevention & control*; D005260:Female; D005602:France / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D008297:Male; D015269:Mycobacterium avium Complex / Q000187:drug effects; D015270:Mycobacterium avium-intracellulare Infection / Q000517:prevention & control*; D012189:Retrospective Studies; D017828:Rifabutin / Q000627:therapeutic use*; D019529:Sexuality; D013997:Time Factors
D000904:Antibiotics, Antitubercular; D017828:Rifabutin